Genistein (Isoflavone · Menopausal Support · Bone Density)

Compound	Genistein
Chemical class	Polyphenol — Isoflavone (5,7,4′-Trihydroxyisoflavone)
CAS	446-72-0
Primary source	Glycine max (soybean), Trifolium pratense (red clover)
Key applications	Phytoestrogenic, bone density, menopausal support
Claim strength	Moderate
Typical form	Genistein 98% isolate; soy isoflavones extract
Buy from Herbuno	Genistein 98% Powder (Soy) | High-Purity Isolate | Glycine max → Soy Isoflavones 80% Powder (Soy Extract) | Standardized Glycine max →

Name origin: From Genista tinctoria (dyer’s greenweed), where genistein was first isolated in 1899, though soybean is the primary commercial source. Genistein is the most studied phytoestrogen and the dominant isoflavone in soy, alongside daidzein. Traditional use: Soy-based fermented foods (tofu, miso, tempeh) have been dietary staples across East Asia for centuries. The low incidence of menopausal hot flushes and breast cancer in Japanese women relative to Western populations prompted research into soy isoflavones as the contributing dietary factor. Research trajectory: Genistein has an extensive clinical evidence base across bone health, menopausal symptoms, cardiovascular risk markers, and cancer prevention (preclinical). It is one of the most researched phytochemicals globally. Commercial source: Genistein is commercially available as a high-purity isolate (98% HPLC) from soy or red clover sources, and as a primary constituent of Soy Isoflavones 80% standardised extract. See sourcing options below.

---

Evidence for Genistein Applications

Menopausal symptom support: Multiple RCTs and meta-analyses demonstrate genistein (54–100 mg/day) significantly reduces hot flush frequency and severity in peri- and postmenopausal women. Effect size is moderate versus placebo (approximately 30–50% reduction in hot flush frequency). ERβ agonism in hypothalamic thermoregulatory pathways is the primary proposed mechanism. Claim strength: Moderate.

Bone density preservation: Genistein activates ERβ in osteoblasts, promoting bone formation, and inhibits osteoclast differentiation. Multiple RCTs in postmenopausal women show genistein (54 mg/day) maintains or improves lumbar spine BMD over 24 months versus placebo. A well-powered Sicilian trial (Marini et al.) demonstrated significant BMD preservation. Claim strength: Moderate.

Cardiovascular risk markers: Genistein reduces LDL-C, improves endothelial function, and reduces homocysteine in human supplementation studies. Effect sizes are modest but consistent across multiple trials. Mechanism includes upregulation of LDL receptors and NO-mediated vasodilation. Claim strength: Moderate.

---

Dosage & Formulator Specification

Menopausal and bone health clinical dose: 40–100 mg/day genistein (aglycone equivalent), typically as a single daily dose. The most studied dose for bone outcomes is 54 mg/day genistein aglycone. For hot flush management, 60–80 mg/day is the effective range in most trials.

Herbuno Genistein 98%: highly pure isolate allowing precise dose formulation. For budget-sensitive formulations, Soy Isoflavones 80% (which delivers genistein alongside daidzein and glycitein in a natural ratio) at 100–125 mg/day provides approximately 40–60 mg genistein equivalent depending on the isoflavone profile of the extract.

Genistein aglycone has low aqueous solubility (~0.01 mg/mL) but is better absorbed than glycoside forms (genistin) because it does not require gut microbial deglycosylation. Specify aglycone versus glycoside form in formulation documentation. Phytosome delivery (1:2 genistein:phosphatidylcholine) improves bioavailability 2–3-fold.

---

Frequently Asked Questions — Genistein

Is genistein safe for women with hormone-sensitive breast cancer history?
This is a clinically debated question. In vitro, genistein can stimulate ERα-positive breast cancer cell proliferation at low concentrations. Epidemiological data from Asian populations (lifetime soy consumers) suggest no increased risk and possibly protective effects. Most oncology guidelines advise caution for individuals with ERα-positive breast cancer history; supplement-level genistein doses should be discussed with the treating oncologist. Formulators should include appropriate advisory language.

What is the difference between genistein and genistin?
Genistin is the 7-O-glucoside (glycoside form) of genistein — the form found naturally in soy. Genistein is the aglycone released by gut microbial or enzymatic hydrolysis. Genistin is more water-soluble but requires conversion before absorption. Fermented soy products (miso, tempeh) contain predominantly the aglycone form due to microbial fermentation, which may explain their superior bioavailability relative to unfermented soy.

Does genistein benefit men as well as women?
Yes. In men, genistein modulates androgen receptor signalling and has shown benefits for prostate health markers (PSA reduction trends) in pilot trials. Bone health benefits apply across genders. Concerns about feminising effects at supplement doses are not supported by clinical evidence — the estrogenic potency of genistein is approximately 100–1000-fold lower than oestradiol.

How should genistein be labelled — as an isoflavone or a phytoestrogen?
Both terms are accurate. “Isoflavone” is the chemical class designation; “phytoestrogen” describes its biological activity. In supplement labelling, “soy isoflavones (genistein)” is the most common and regulatory-friendly declaration. Avoid “oestrogen” without the “phyto” qualifier to prevent confusion with pharmaceutical oestrogen therapy.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery